Study #2023-1053
An open-label, multicenter phase 1/2 study to evaluate the safety and efficacy of AB-2100 in patients with recurrent advanced or metastatic clear-cell renal cell carcinoma (ccRCC)
MD Anderson Study Status
Enrolling
Treatment Agent
AB-2100
Description
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Study phase:
Physician name:
Samer Srour
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-734-0338
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.